Investigational drug · Phase 2
UCART22
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for B-cell Acute Lymphoblastic Leukemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "UCART22"
First trial start
2019
Oct 14, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "UCART22", any sponsor or status.
Conditions studied
As listed on its trial records.
- B-cell Acute Lymphoblastic Leukemia
Approved drugs for the same conditions: Acute lymphoblastic leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "UCART22" as an intervention, largest first.
- Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)Active, not recruiting
Cellectis S.A.Industry
NCT04150497 · 45 participants · Start Oct 14, 2019 · Primary completion Sep 16, 2026
Drug: UCART22; CLLS52 · For: B-cell Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for B-cell Acute Lymphoblastic Leukemia
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- single CNCT19Phase 23 trials
Juventas Cell Therapy Ltd. · Relapsed or Refractory Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
- YK012Phase 22 trials
Excyte Biopharma Ltd · Systemic Lupus Erythematosus (SLE), B-cell Acute Lymphoblastic Leukemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.